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Background: The status of immunocompromised patients is well recognized in end stage renal disease (ESRD). As
described recently, this acquired immune dysfunction in the uremic milieu may be one of the main pathogenic
factors for mortality in ESRD. The aim of this study was to determine the relationship between the immune
response following a hepatitis B vaccination (HBV vaccination) and the survival of maintenance dialysis patients.
Methods: A total of 156 patients (103 on hemodialysis and 53 on continuous ambulatory peritoneal dialysis) were
recruited. After receiving a full dose of the HBV vaccination, all patients were followed up for to 5 years to evaluate
the association of patient survival, cause of mortality, and immune response.
Results: The response rate to the hepatitis B vaccination was 70.5%. There was no significant association between
the immune response and the 5-year survival rate (p =0.600) or between the post-vaccination anti-HBs titers and
the 5-year survival rate (p = 0.201). The logistic prediction model with the coefficient as non-response following HBV
vaccination, diabetes mellitus, old age, and low albumin level could significantly predict infection-cause mortality
(sensitivity = 0.842, specificity = 0.937).
Conclusion: There was no significant association between the immune response to HBV vaccination and the 5-year
survival rate. However, non-response following HBV vaccination might be associated with infection-cause mortality
in dialysis patients.
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End-stage renal disease (ESRD) significantly increases
the risk of mortality and morbidity. The leading cause of
death in ESRD is cardiovascular disease (CVD), which
accounts for more than half of deaths in uremic patients,
with infection the second leading cause [1,2]. Previous
studies have investigated the relationships among endo-
thelial dysfunction, inflammation, and atherosclerotic
vascular disease in chronic kidney disease [3,4]. Uremic-
related inflammation, which commonly occurs during
pre-dialysis and persists even after dialysis, is now
regarded as an important predictor of cardiovascular
and all-cause mortality in the ESRD population [5].* Correspondence: liuyaolung@yahoo.com
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reproduction in any medium, provided the orCurrently, it is speculated that acquired immune dys-
function in the uremic milieu may be one of the main
pathogenic factors, mediated through CVD and infec-
tions, in most ESRD-related deaths. Concomitant im-
munosuppression and immune activation in uremia
would predispose patients to infection and CVD, re-
spectively [6].
Although it is well established that aging, diabetes
mellitus (DM), and the presence of co morbid conditions
predict a poor prognosis in ESRD, few studies have
investigated immune dysregulation as a determinant of
mortality in ESRD [7]. Furthermore, acquired immune
dysfunction in uremic patients has various clinical fea-
tures, ranging from proness to infection to impaired im-
mune response to vaccinations. The aim of our study
was to link the clinical immune parameter, immune re-
sponse and anti-HBs titers one month following HBV
vaccination with mortality in ESRD populations.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of HBV vaccine
responders and non-responders
Characteristic Non-responders Responders P value
Number of pts. 46 110
Age 62.63 ± 9.95 55.75 ± 14.31 0.003
Gender(M/F) 17/29 47/63 0.507
DM 19 31 0.111
HCV infection 9 (19.6%) 15 (13.6%) 0.353
Hemoglobin(g/dL) 9.49 ± 1.42 9.55 ± 1.38 0.786
Albumin(g/dL) 3.47 ± 0.37 3.50 ± 0.39 0.696
Dialysis modality (HD:PD) 31:15 72:38 0.817
Cholesterol(mg/dL) 184.71 ± 50.07 181.33 ± 42.66 0.669
Triglyceride(mg/dL) 187.93 ± 131.87 176.58 ± 124.46 0.610
Note: data are shown as the number (%) or mean ± SD, as appropriate.
Abbreviations: M, male; F, female.
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This clinical study complied with the Declaration of Hel-
sinki and was approved by the Medical Ethics Commit-
tee of the China Medical University Hospital, Taichung
(Taiwan, ROC).
This was a retrospective study of ESRD patients who
underwent dialysis therapy at the dialysis unit of the
China Medical University Hospital (Taichung, Taiwan)
from March 2002 to March 2008 and who were followed
up until March 2009.
The HBV vaccine was offered to all patients who
tested negative for the HBV surface antigen (HBs Ag)
and anti-HBs and who had not previously received the
HBV vaccination. We excluded patients who had malig-
nancies, who were receiving immunosuppressive agents,
or who did not receive all four vaccinations. All patients
were given four doses (40 μg per dose) of the hepatitis B
vaccine (Engerix-B, GlaxoSmithKline Biologicals, Phila-
delphia, USA) in the deltoid muscles at 0, 1, 2, and
6 months. Anti-HBs titers were measured by an ELISA
kit (AUSAB-EIA, Abbot Labs, Chicago, USA) one month
after the final dose and annually thereafter.
We defined responders and non-responders according
to the level of anti-HBs one month after the final injec-
tion (non-responders: < 10 IU/L; responders: ≥ 10 IU/L).
These patients were followed up to assess the relation-
ship between the initial immune response to vaccination
and the 5-year-survival. In addition, over the 5-year fol-
low-up period, we assessed the effect of one-month
post-vaccination anti-HBs titers on survival.
To determine the factors related to HBs antibody for-
mation following vaccination, we recorded the patient age,
gender, presence of diabetes mellitus (DM), hemoglobin,
serum albumin, triglyceride, cholesterol, fasting blood
sugar, presence of hepatitis C antibodies, and dialysis mo-
dality at the initiation of vaccination [8-10].
Statistical analysis
All statistical tests were performed with SPSS (version
15.0). A P value < 0.05 was considered statistically signifi-
cant. For categorical variables, we used the Chi-squared
test and presented data as absolute numbers or percen-
tages. For continuous variables, we used Student’s t-test
and presented the data as means ± standard deviations.
The Cox regression model was used to investigate the as-
sociation between seroconversion and mortality and the
relationship between post-vaccination anti-HBs titers
and mortality.
We adjusted for age, level of albumin, presence of
DM, dialysis modality, and gender to determine the
adjusted hazard ratios with the immune response to
mortality.
We adapted the logistic regression model as fol-
lows: β0+ β1*Non-response + β2*(presence of DM)+β3*Age+β4*Albumin+β5*(presence of DM)*Albumin +
β6*Age*Albumin. We used this equation to evaluate
the effects of non-response, diabetes mellitus, age,
and the level of albumin in predicting mortality due
to infection.
Results
A total of 156 patients (64 males, 92 females) were
recruited, with 110 responders and 46 non-responders
(Table 1). Mean ages were higher for non-responders
(62.63±9.95 years) than for responders (55.75±14.31 years,
P = 0.003). The prevalence of diabetes or anti-HBV vaccin-
ation at the start of the study was 32.0%.
Univariate analysis indicated no significant differences
between responders and non-responders in terms of gen-
der, presence of DM, presence of hepatitis C antibodies,
hemoglobin, albumin, dialysis modality, triglyceride,
cholesterol, and several other relevant factors (Table 1).
By the time of the 5-year follow up, 35 patients had died.
The most common cause of death was infection (54.3%;
19 patients, including 8 cases of severe pneumonia, 4
cases of peritonitis, 2 cases of infective endocarditis, and
1 case of either meningitis, diabetic foot infection, septic
arthritis, urosepsis, and septicemia), followed by cardio-
vascular events (25.7%, 9 patients), gastrointestinal bleed-
ing (5.7%, 2 patients), gastrointestinal perforation (5.7%,
2 patients), and others (8.6%, 3 patients). By the end of
the study, the prevalence of DM in all available subjects
(including those that died during the study) was 30%, but
the impact of DM on the loss of anti-HBs Ab was not
significant (p = 0.308).
We followed up on all patients after the vaccination to
investigate the association between seroconversion and
mortality. Figure 1 shows that there was no significant
survival difference for responders and non-responders
(P = 0.297). A Cox regression analysis, which considered
patient age, presence of DM, initial serum albumin
Figure 1 Cumulative survival of HBV vaccine responders and non-responders over 5 years.
Table 3 The predictive model of infection-cause mortality
in dialysis patients Logit (probability of infection-cause
mortality) =β0+β1*Retiter +β2*DM+β3*Age+
β4*Albumin+β5*DM*Albumin+β6*Age*Albumin
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modality, and gender, showed that advanced age and
malnutrition were associated with increased mortality
(P = 0.035 and P= 0.032, respectively) (Table 2).
We also evaluated the association between one-month
post-vaccination anti-HBs titers and mortality. There
was no significant survival difference between immune
sustainers and non-sustainers (P = 0.201). Cox regression
analysis indicated that only age and low levels of albu-
min were associated with mortality (p = 0.04 and
p = 0.032, respectively).
The predictive model of mortality due to infection in
dialysis patients demonstrated that non-response, DM,
age, and low levels of albumin all predicted significantly
higher mortality rates due to infection (Table 3). This
model performs well and has high sensitivity and high
specificity (sensitivity = 0.842, specificity = 0.938, positive
predictive values = 0.941, negative predictive value =Table 2 Cox proportional hazards regression of immune




Seroconversion of HBV vaccination 0.600
Albumin 0.032
Gender 0.060
Diabetes Mellitus 0.6700.833). The area under the ROC curve (AUC) provides
an overall measure of the model’s classification accuracy,
with a value of one representing perfect accuracy. The
ROC curve shows a high capacity for discriminating
infection-cause mortality vs. non-infection cause mortal-
ity, with an AUC=0.9112 (Figure 2). The immune re-
sponse following HBV vaccination and other co-factors
were not associated with CV mortality (data not shown).
Discussion
In this study, we showed that the seroconversion rate of
our dialysis patients was 70.5% after four double doses
(40 μg per dose) of the hepatitis B vaccine administered











Sensitivity: 0.8421 ; Specificity: 0.9375
PPV: 0.9412 ; NPV: 0.8333
Figure 2 The ROC curve shown used to examine the performance of logistic regression model.
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Seroconversion to HBV vaccination and one-month
post-vaccination anti-HBs titers did not predict all-cause
mortality in our maintenance dialysis patients. After
adjusting for age, DM, albumin levels, gender, and dialy-
sis modality, non-seroconversion following HBV vaccin-
ation could independently predict mortality due to
infection in ESRD dialysis patients. This novel and inter-
esting finding demonstrates the possible relationship be-
tween the vaccination response and the specific cause of
mortality in ESRD patients.
Our study dialysis subjects displayed a similar subopti-
mal immune response to patients in previous studies. In
ESRD patients, the response rate to HBV vaccination is
approximately 50%–80%, which is lower than the 90%
response rate in the general population, with advanced
age being a significant negative factor associated with
this poor immune response [11-13]. Numerous factors
associated with the impaired immune response following
HBV vaccination in ESRD, such as age, albumin levels,
HCV infection, and gender, have been well studied
[8-10,13]. Current studies have focused on the insufficient
acquired immunity due to uremia to account for the sub-
optimal response rates following HBV vaccination [14].
Recent studies have proposed that the immunodeficiency
in ESRD results from the impaired function of antigen-
presenting cells, alteration of toll-like receptors, weakened
activation of T lymphocytes, and the imbalance of T-
helper lymphocytes (Th 1/Th 2 ratio) [14-16].In the present study, we demonstrated that DM, age,
low albumin levels, and non-response following HBV
vaccination could predict mortality due to infection.
Several negative determinants of mortality in ESRD,
such as old age, DM, and malnutrition, have been docu-
mented [7]. Immune dysfunction in uremia is also
recognized as a determinant of mortality. However, our
findings are important because they demonstrate a link
between infection-cause mortality and insufficient im-
mune responses to HBV vaccination in ESRD, since
these two clinical presentations involve homogenous but
varied interactions between the immune, innate immune
and the adaptive immune systems. A recent review indi-
cated that in dialysis patients innate immunity plays an
important role in fighting infections, while acquired im-
munity (via antibody production) also makes a signifi-
cant contribution [14]. We therefore hypothesize that T
cell dysfunction may be the main link between the high
mortality due to infection and the insufficient antibody
response to vaccination in ESRD patients. Impaired
cytotoxic CD8 T cell response limits the fight of the
infected host defense system against the pathogens,
while the inadequate function of helper CD4 T cells
weakens the humoral immune system. The results of
studies by Alvarez-lara et al. and Meier P et al. support
this hypothesis, finding increased apoptosis of T cells in
uremia [17-19]. An alternative interpretation is that the
key linking factor between high mortality due to infec-
tion and the impaired vaccination response lies upstream
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the antigen presenting cell or secondary dysregulation or
activation of cytokines [6,14,20].
It has been proposed that both the innate and acquired
immune systems may play a role in the progression of
atherosclerosis, the major pathogenic factor responsible
for most deaths in ESRD patients [21]. Interestingly, we
did not find an association between seroconversion and
all-cause mortality or between seroconversion and CV-
cause mortality in dialysis patients. The correlations
among persistent inflammation, CVD, immune dysfunc-
tions, and infections in ESRD have become apparent in
recent years [5,6,22-24].
Chronic inflammation as a result of hypercytokinemia
and an imbalance in the pro-inflammatory to anti-
inflammatory ratio has been well recognized in ESRD
[25]. The dysregulation of various cytokines due to the
uremia milieu may link inflammation-atherosclerosis to
impaired immunity inflammation in dialysis patients
[14]. Several studies have attempted to link the levels
and types of cytokines with clinical outcomes. Girndt
et al. determined that higher levels of IL-6 and TNF-α
correlated with an immunocompromised status, that is,
non-seroconversion to HBV vaccinations in HD patients
[26]. Kimmel et al. assessed immune parameters such as
cytokines in 230 HD patients, with a three-year follow
up. Their results showed that increased levels of IL-6,
TNF-α, IL-1, and IL-13 correlated with a higher relative
mortality risk. High levels of IL-2, IL-4, IL-5, and IL-12,
and T cell functions were associated with survival in HD
patients. The authors did not analyze the causes of mor-
tality in their patients or further investigate the associa-
tions between the causes of mortality and cytokines.
Interestingly, they noted that the patterns of cytokines
involved may be more important than the individual
cytokine levels in interpreting survival outcomes [27].
Among the other studies on cytokines’ ability to pre-
dict mortality in ESRD, the study by Badiou et al. mea-
sured levels of both pro-inflammatory cytokines and
anti-inflammatory cytokines in 134 HD patients and
found that IL-6 levels could strongly predict CV mortal-
ity. In addition, (IL-4+ IL-6+ IL-10)/(IL-2 + IFN-γ) was
associated with non-CV mortality. The authors specu-
lated that examination of the Th1/Th2 cytokine relation
might be more relevant for predicting non-CV mortality
[28]. These findings indicate that the laboratory immune
parameter, especially the Th1/Th2 cytokine ratio that
implies defective immunity, may be able to predict clin-
ical outcomes. The clinical immune parameters and the
immune response following HBV vaccination may be
able to correlate with mortality in ESRD patients.
The study by Fernandez et al. of 64 HD patients noted
that low levels of albumin negatively influenced the re-
sponse to HBV vaccination. In the study’s survivalanalysis of 31 patients, non-responders had higher mor-
tality and morbidity [29]. The authors did not adjust for
albumin levels or age in the survival analysis of these
HD subjects. However, our Cox regression survival ana-
lysis of 156 dialysis patients reveals that only old age and
low levels of albumin have significantly higher mortality
but that non-response following HBV vaccination did
not. Since low albumin levels are recognized as an inde-
pendent factor of mortality in ESRD [30], we speculate
that low albumin levels account for the concomitant
impaired immune response following HBV vaccination
and increased mortality in the Fernandez et al. study.
The Kimmel et al. study suggests that better T cell
function and humoral immunity are associated with a
survival advantage in HD patients [27]. Unlike the pre-
dictive value of the cytokine ratio on mortality men-
tioned above, our study demonstrated no significant
relationship between the clinical immune response fol-
lowing HBV vaccination and all-cause mortality. The
levels and types of cytokines in dialysis patients were
the result of the interacting influences of residual renal
function, dialysis adequacy, comorbidity, and current
treatment [31]. Our dialysis patients received HBV vac-
cinations at the initiation of renal replacement therapy.
Some of our study subjects, especially the PD patients,
retained some residual renal function, which would
affect the immune response to HBV vaccinations. In
the Badiou et al. and Kimmel et al. studies, the levels
of circulating cytokines (either Th1 or Th2-related)
were significantly higher in the HD patients than in
the control patients [27,28]. The effects of these un-
usual levels of circulating cytokines may not correlate
well with their baseline local immunological functions
[31]. These circulating cytokines may operate in a
more sophisticated pathophysiologic network, causing
erythropoietin resistance, hypoalbuminemia, frailty, ath-
erosclerosis, and dyslipidemia [31,32]. Therefore, the
clinical outcomes, survival and immune response fol-
lowing HBV vaccination may be the diverse results of
the differing interactions of various cytokines at spe-
cific cellular, organ, and system targets. We therefore
could not determine whether a direct association exists
between seroconversion and all-cause mortality in dia-
lysis patients despite the well-recognized immunodefi-
ciency, hypercytokinemia, and high mortality in ESRD
populations [1,14,24,33,34].
We did not check the antibody of the core HBV anti-
gen (anti-HBc). The finding of a positive anti-HBc in the
absence of HBs Ag or anti-HBs is relatively uncommon
[35]. Chen et al. found that the responsiveness rates of
the hepatitis B vaccination were the same between iso-
lated anti-HBc positive and normal subjects [36].
We recognize that our study has certain limitations,
such as the relatively small number of dialysis patients
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tality. Moreover, infection was the leading cause of mor-
tality among our study subjects, despite being the
second leading cause of deaths in the ESRD population
as a whole. The immune status of dialysis patients may
change after losing residual renal function. The results
of our study need to be replicated in prospective studies
of using larger populations of chronic, stable dialysis
patients.
Conclusions
In conclusion, we demonstrated that non-response fol-
lowing HBV vaccination might be associated with
infection-cause mortality in our dialysis patients. How-
ever, the clinical immune response following HBV vac-
cination would not be associated with all-cause mortality
in our dialysis patients.
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